Bovilis Leptavoid-H
ATC code
Species
Cattle.
Indications
For the active immunisation of cattle from 1 month of age against Leptospira interrogans serovar Hardjoand Leptospira borgpetersenii serovar Hardjo.
To reduce shedding of Leptospira interrogans serovar Hardjo in urine. To improve herd fertility when infertility is diagnosed as caused by Leptospira Hardjo.
Circulating antibody is detectable 14 days following the first injection and persists for 12 months following completion of the primary course. Conjunctival challenge demonstrates 12 months cross protection against Leptospira borgpetersenii serovar Hardjo subtype Hardjobovis.
In addition to the circulating antibody response, vaccination with Bovilis
Leptavoid-H also stimulates cell-mediated immunity to Leptospira borgpetersenii serovar Hardjo which is maintained for at least five months and responds in the event of a challenge five months post vaccination.
Dose to be administered and administration route
Minimum age of administration: 1 month.
Dose: 2 ml.
Route of administration: Subcutaneous injection.
The container should be well shaken to re-suspend the precipitate before doses are withdrawn. The vaccine should be deposited beneath the skin covering the chest wall, well behind the shoulder, or beneath the skin covering the side of the neck.
Syringes and needles should be sterilised before use and the injection made subcutaneously through an area of clean, dry skin taking precautions against contamination. Exercise care with part used containers and discard all part used containers within 8 hours of opening to reduce the potential for contamination. Use a draw-off needle in the vial stopper to avoid excess broaching of the stopper.
Vaccination regime
Primary course
The primary course consists of two doses with an interval of at least 4 weeks and not more than 6 weeks between them. Ideally the course should be completed in the spring before the main season of transmission of Leptospira Hardjo.
Re-vaccination
Re-vaccination with a single dose should be given annually to maintain protection against infection and progressively reduce exposure in the herd. If the primary course is given later than the spring, the first booster should be given in the following spring and annually thereafter.
Youngstock vaccination
If the calves are inoculated before 5 months of age, a further primary course should be given at that age (allowing an interval of 4 weeks between vaccinations), as otherwise maternally derived antibodies may interfere with the immune response.
Older calves not immediately exposed to infection can be given the initial course at any time, but it is advisable to complete vaccination shortly before the main season of transmission of leptospirosis.
To improve herd fertility
For maximum benefit the primary course should be completed within 12 months of infertility being diagnosed as caused by Leptospira Hardjo.
Adverse reactions
A transient rise in temperature of 1 – 1.3 °C lasting 24 – 48 hours after vaccination may occur, particularly after the second dose. This reaction is very common.
Administration of the first and second dose may produce swellings in most animals with diameters of up to 7.5 and 8.5cm respectively. These local reactions normally resolve over several weeks after administration, but may persist for longer in a small number of animals. Local reactions are very common.
Occasional hypersensitivity reactions may occur. In the case of hypersensitivity the use of adrenaline or other appropriate treatment is recommended.
Youngstock vaccination
The sizes of the reactions seen in the second primary course may be larger than those seen in the first primary course (up to 17 cm after 5 vaccinations 28 days apart).
There may also be an increased sensitivity at the injection site compared to the primary vaccination. Animals may also exhibit a transient rise in temperature of 1.2 – 2.6 °C following the second primary course. See section 4.9 for dosing recommendations.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).
